18744136. TIS-L TARGETING ANTIVIRAL ANTISENSE OLIGONUCLEOTIDE WITH ABILITY TO INHIBIT VIRAL REPLICATION OF SARS-COV-2 (KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY)

TIS-L TARGETING ANTIVIRAL ANTISENSE OLIGONUCLEOTIDE WITH ABILITY TO INHIBIT VIRAL REPLICATION OF SARS-COV-2

Organization Name

KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor(s)

Daehyun Baek of Seoul (KR)

Hee Ryung Chang of Seoul (KR)

Jeong-Sun Yang of Cheongju-si (KR)

Hansaem Lee of Cheongju-si (KR)

Man-Seong Park of Seoul (KR)

Heedo Park of Seoul (KR)

Yoon Ki Kim of Daejeon (KR)

Jeeyoon Chang of Daejeon (KR)

Joori Park of Seoul (KR)

Joo-Yeon Lee of Cheongju-si (KR)

Kyung-Chang Kim of Cheongju-si (KR)

TIS-L TARGETING ANTIVIRAL ANTISENSE OLIGONUCLEOTIDE WITH ABILITY TO INHIBIT VIRAL REPLICATION OF SARS-COV-2

This abstract first appeared for US patent application 18744136 titled 'TIS-L TARGETING ANTIVIRAL ANTISENSE OLIGONUCLEOTIDE WITH ABILITY TO INHIBIT VIRAL REPLICATION OF SARS-COV-2

Original Abstract Submitted

The present disclosure relates to a TIS-L targeting antisense oligonucleotide that inhibits the viral replication of SARS-COV-2 and antiviral use thereof. Since the TIS-L targeting antisense oligonucleotide according to the present disclosure has a simple structure, it is easy to mass produce, and as it exhibits antiviral efficacy of 90% or more even at low doses against the original strain and various modified strains of the virus, it can be advantageously utilized in the development of COVID-19 treatment.